Discover 775 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 775
Active & Responsive
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
for
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma,
Location: Washington D.C. DC
Sponsor: Children's National Research Institute
Sex: All
Age: 3 - 25
Code: NCT07664176
Phase 1, Recruiting
Active & Responsive
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
for
Neurofibromatosis 1, Plexiform Neurofibroma
Location: Washington D.C. DC, Philadelphia PA, Boston MA,
Location: Washington D.C. DC, Wilmington DE, Philadelphia PA,
Sponsor: Mezzion Pharma Co. Ltd
Sex: All
Age: 12 - 18
Code: NCT05918211
Phase 3, Recruiting
Active & Responsive
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
for
Pleuropulmonary Blastoma
Location: Washington D.C. DC, Baltimore MD, Charlottesville VA,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT06647953
Phase 3, Recruiting
Active & Responsive
A Prospective Analysis of Long-Term Clinical Outcomes and 3D Spine Growth in Anterior Vertebral Body Tethering
for
Scoliosis Idiopathic
Location: Washington D.C. DC, Philadelphia PA, New York NY,
Sponsor: Pediatric Spine Foundation
Sex: All
Age: 0 - 18
Code: NCT04914507
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
for
Phelan-McDermid Syndrome
Location: Washington D.C. DC, Chevy Chase MD, Charlottesville VA,
Sponsor: Neuren Pharmaceuticals Limited
Sex: All
Age: 3 - 12
Code: NCT07281079
Phase 3, Recruiting
Active & Responsive
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
for
Turner Syndrome, Short Stature Homeobox Gene Mutation,
Location: Washington D.C. DC, Charlottesville VA, Wilmington DE,
Sponsor: Ascendis Pharma A/S
Sex: All
Age: 2 - 17
Code: NCT07221851
Phase 3, Recruiting
Active & Responsive
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
for
Oral Mucositis, Periodontal Diseases, Cancer
Location: Washington D.C. DC
Sponsor: Georgetown University
Sex: All
Age: 25 - 70+
Code: NCT06315855
Recruiting
Active & Responsive
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
for
HER2-positive Metastatic Breast Cancer
Location: Washington D.C. DC, Baltimore MD, Philadelphia PA,
Sponsor: Abramson Cancer Center at Penn Medicine
Sex: All
Age: 18+
Code: NCT06551116
Recruiting
Active & Responsive
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT05661201
Phase 1, Recruiting
Active & Responsive
Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors
for
Insomnia
Location: Washington D.C. DC
Sponsor: Georgetown University
Sex: Male
Age: 21+
Code: NCT07128927
Recruiting
Active & Responsive
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
for
Thyroid Cancer
Location: Washington D.C. DC, Falls Church VA
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT06980103
Recruiting
Active & Responsive
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Washington D.C. DC, Fairfax VA, New York NY,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07111520
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer,
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT06901531
Phase 3, Recruiting
Active & Responsive
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
for
Immune Thrombocytopenic Purpura (ITP)
Location: Washington D.C. DC, Bethesda MD, Philadelphia PA,
Sponsor: Takeda
Sex: All
Age: 18+
Code: NCT06722235
Phase 3, Recruiting
Active & Responsive
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
for
Carcinoma, Non-Small Cell Lung
Location: Washington D.C. DC, Baltimore MD
Sponsor: Georgetown University
Sex: All
Age: 18+
Code: NCT04499053
Phase 2, Recruiting
Active & Responsive
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
for
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Location: Washington D.C. DC, Hackensack NJ
Sponsor: Georgetown University
Sex: Female
Age: 18+
Code: NCT05256745
Phase 1, Phase 2, Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: Washington D.C. DC, Baltimore MD, Martinsburg WV,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase 3, Recruiting
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
for
Recurrent Head and Neck Squamous Cell Carcinoma,
Location: Washington D.C. DC, Columbia MD, Glen Burnie MD,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04671667
Phase 2, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Washington D.C. DC, Silver Spring MD, Clinton MD,